MX2020010075A - Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos. - Google Patents
Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos.Info
- Publication number
- MX2020010075A MX2020010075A MX2020010075A MX2020010075A MX2020010075A MX 2020010075 A MX2020010075 A MX 2020010075A MX 2020010075 A MX2020010075 A MX 2020010075A MX 2020010075 A MX2020010075 A MX 2020010075A MX 2020010075 A MX2020010075 A MX 2020010075A
- Authority
- MX
- Mexico
- Prior art keywords
- lysin
- constructs
- lysines
- encode
- isolated
- Prior art date
Links
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title abstract 4
- 102000040430 polynucleotide Human genes 0.000 title abstract 2
- 108091033319 polynucleotide Proteins 0.000 title abstract 2
- 239000002157 polynucleotide Substances 0.000 title abstract 2
- 239000004472 Lysine Substances 0.000 title 1
- 150000002669 lysines Chemical class 0.000 title 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 8
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650235P | 2018-03-29 | 2018-03-29 | |
| US201862721969P | 2018-08-23 | 2018-08-23 | |
| US201862722793P | 2018-08-24 | 2018-08-24 | |
| PCT/US2019/024912 WO2019191633A2 (en) | 2018-03-29 | 2019-03-29 | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020010075A true MX2020010075A (es) | 2021-01-08 |
Family
ID=68060804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010075A MX2020010075A (es) | 2018-03-29 | 2019-03-29 | Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11773140B2 (https=) |
| EP (1) | EP3775192A4 (https=) |
| JP (1) | JP2021519083A (https=) |
| KR (1) | KR20200136980A (https=) |
| CN (1) | CN112368376A (https=) |
| AU (1) | AU2019245369A1 (https=) |
| BR (1) | BR112020019484A2 (https=) |
| CA (1) | CA3095484A1 (https=) |
| IL (1) | IL277119B2 (https=) |
| MX (1) | MX2020010075A (https=) |
| WO (1) | WO2019191633A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015200783A2 (en) * | 2014-06-26 | 2015-12-30 | The Rockefeller University | Acinetobacter lysins |
| WO2019118632A1 (en) | 2017-12-12 | 2019-06-20 | Contrafect Corporation | Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa |
| WO2019191633A2 (en) | 2018-03-29 | 2019-10-03 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| US10988520B2 (en) * | 2018-03-29 | 2021-04-27 | Contrafect Corporation | Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| US20210330738A1 (en) * | 2018-03-29 | 2021-10-28 | Contrafect Corporation | Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria |
| EP3840771A4 (en) * | 2018-08-23 | 2023-04-19 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| CN114040773A (zh) * | 2019-04-05 | 2022-02-11 | 康特拉费克特公司 | 在存在人血清的情况下对铜绿假单胞菌具有杀菌活性的溶素及其衍生物 |
| KR20220029746A (ko) * | 2019-07-05 | 2022-03-08 | 콘트라펙트 코포레이션 | 항미생물성 박테리오파지 유도된 폴리펩타이드 및 이의 그람 음성 및 항산성 세균에 대한 사용 |
| EP4058468A4 (en) * | 2019-11-14 | 2024-04-10 | Contrafect Corporation | POLYPEPTIDE CONSTRUCTIONS OF ANTIMICROBIAL PEPTIDE LYSINE (AMP), LYSINES, ISOLATED POLYNUCLEOTIDES ENCODING THEREFOR AND USES THEREOF |
| WO2021211303A1 (en) * | 2020-04-14 | 2021-10-21 | Contrafect Corporation | Antiviral, bacteriophage-derived polypeptides and their use against viruses |
| US20210324359A1 (en) * | 2020-04-17 | 2021-10-21 | Contrafect Corporation | Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis |
| KR20230162045A (ko) * | 2021-03-26 | 2023-11-28 | 콘트라펙트 코포레이션 | 그램-음성 박테리아에 대해 활성인 아무린, 리신, 및 리신-항미생물 펩타이드 (amp) 작제물 |
| WO2022236088A1 (en) * | 2021-05-06 | 2022-11-10 | Bioharmony Therapeutics Inc. | Lysin polypeptide compositions and methods of use |
| FR3149209B1 (fr) * | 2023-06-02 | 2026-04-03 | Oreal | Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un alcool aromatique |
| FR3149202B1 (fr) * | 2023-06-02 | 2026-04-10 | Oreal | Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et une huile. |
| EP4719330A1 (en) * | 2023-06-02 | 2026-04-08 | L'oreal | Cosmetic composition comprising an endolysin derived from a staphylococcus aureus phage and an aromatic alcohol |
| FR3149203B1 (fr) * | 2023-06-02 | 2026-03-13 | Oreal | Composition anhydre comprenant une endolysine et de l’hydroxypropylmethylcellulose et/ou du pullulane |
| WO2024256710A2 (en) | 2023-06-15 | 2024-12-19 | Aurobac Therapeutics Sas | Engineered lysin polypeptide constructs active against gram-negative bacteria |
| WO2025054593A2 (en) * | 2023-09-07 | 2025-03-13 | The Trustees Of The University Of Pennsylvania | Molecular de-extinction of antibiotics enabled by deep learning |
| CN120924524B (zh) * | 2025-10-14 | 2026-01-06 | 中国海洋大学 | 一种抗菌肽及其制备方法和在制备治疗肺炎的制剂中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0517477A (pt) | 2004-11-12 | 2008-10-07 | Novozymes As | polipeptìdeo, construção de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, métodos para produzir um polipeptìdeo, um polinucleotìdeo, e uma proteìna, planta, parte de planta ou célula vegetal transgênicas, método para matar ou inibir o crescimento de células microbianas, e, uso de um polipeptìdeo antimicrobiano |
| SG176783A1 (en) | 2009-06-16 | 2012-01-30 | Univ Tokai | Anti-gram-negative bacteria agent |
| PL2445515T3 (pl) * | 2009-06-26 | 2016-10-31 | Środki przeciwdrobnoustrojowe | |
| AU2010264659B2 (en) * | 2009-06-26 | 2016-08-04 | Lysando Aktiengesellschaft | Antimicrobial agents |
| KR20120059576A (ko) | 2009-08-24 | 2012-06-08 | 뤼산도 홀딩 아게 | 신규한 엔도리신 ＯＢＰｇｐＬＹＳ |
| EP2468856A1 (en) | 2010-12-23 | 2012-06-27 | Lysando Aktiengesellschaft | Antimicrobial Agents |
| EP2699689A4 (en) | 2011-04-21 | 2014-12-17 | Univ Utrecht Holding Bv | STREPTOCOCCUS BACTERIOPHAGEN LYSINE FOR THE TREATMENT OF GRAM-POSITIVE BACTERIA IN PETS AND UTILITIES |
| EP2702070B1 (en) | 2011-04-27 | 2015-09-30 | Lysando AG | New antimicrobial agents |
| WO2012159774A1 (en) | 2011-05-26 | 2012-11-29 | Dsm Ip Assets B.V. | Novel listeria bacteriophage p825n and uses thereof |
| US8790639B2 (en) | 2012-03-28 | 2014-07-29 | The United States Of America, As Represented By The Secretary Of Agriculture | Enhanced antimicrobial lytic activity of a chimeric Ply187 endolysin |
| KR101391332B1 (ko) | 2012-05-18 | 2014-05-07 | 연세대학교 산학협력단 | 카바페넴 제제에 내성을 보이는 아시네토박터 속의 균을 용균하는 박테리오파아지 |
| US9388400B2 (en) * | 2012-06-29 | 2016-07-12 | Lysando Ag | Composition for use in mycobacteria diagnosis |
| CN102861324A (zh) * | 2012-10-17 | 2013-01-09 | 重庆市第三人民医院 | 治疗耐碳青霉烯类鲍曼不动杆菌感染的生物试剂 |
| WO2015200783A2 (en) | 2014-06-26 | 2015-12-30 | The Rockefeller University | Acinetobacter lysins |
| EP4115897A1 (en) | 2015-09-17 | 2023-01-11 | Contrafect Corporation | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby |
| KR102000120B1 (ko) | 2017-01-26 | 2019-07-15 | 주식회사 코미팜 | 이유 자돈의 대장균증을 예방하기 위한 재조합 p22 라이소자임 - pmap36 융합 단백질을 이용한 장내독소형 대장균(etec) 고스트 백신 조성물 |
| WO2019118632A1 (en) | 2017-12-12 | 2019-06-20 | Contrafect Corporation | Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa |
| US20210330738A1 (en) | 2018-03-29 | 2021-10-28 | Contrafect Corporation | Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria |
| WO2019191633A2 (en) | 2018-03-29 | 2019-10-03 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| US10988520B2 (en) | 2018-03-29 | 2021-04-27 | Contrafect Corporation | Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| EP3840771A4 (en) * | 2018-08-23 | 2023-04-19 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| US20210324359A1 (en) * | 2020-04-17 | 2021-10-21 | Contrafect Corporation | Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis |
-
2019
- 2019-03-29 WO PCT/US2019/024912 patent/WO2019191633A2/en not_active Ceased
- 2019-03-29 BR BR112020019484-0A patent/BR112020019484A2/pt unknown
- 2019-03-29 CN CN201980036007.XA patent/CN112368376A/zh active Pending
- 2019-03-29 IL IL277119A patent/IL277119B2/en unknown
- 2019-03-29 KR KR1020207031049A patent/KR20200136980A/ko active Pending
- 2019-03-29 JP JP2020551860A patent/JP2021519083A/ja active Pending
- 2019-03-29 EP EP19776817.9A patent/EP3775192A4/en not_active Withdrawn
- 2019-03-29 AU AU2019245369A patent/AU2019245369A1/en not_active Abandoned
- 2019-03-29 CA CA3095484A patent/CA3095484A1/en active Pending
- 2019-03-29 MX MX2020010075A patent/MX2020010075A/es unknown
- 2019-03-29 US US17/041,691 patent/US11773140B2/en active Active
-
2023
- 2023-08-18 US US18/452,038 patent/US20240018192A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3775192A2 (en) | 2021-02-17 |
| JP2021519083A (ja) | 2021-08-10 |
| AU2019245369A1 (en) | 2020-10-29 |
| IL277119A (en) | 2020-10-29 |
| EP3775192A4 (en) | 2022-06-01 |
| WO2019191633A2 (en) | 2019-10-03 |
| CN112368376A (zh) | 2021-02-12 |
| BR112020019484A2 (pt) | 2021-01-12 |
| US20210047374A1 (en) | 2021-02-18 |
| CA3095484A1 (en) | 2019-10-03 |
| KR20200136980A (ko) | 2020-12-08 |
| US11773140B2 (en) | 2023-10-03 |
| WO2019191633A3 (en) | 2019-11-07 |
| US20240018192A1 (en) | 2024-01-18 |
| RU2020129467A (ru) | 2022-05-04 |
| IL277119B2 (en) | 2025-08-01 |
| IL277119B1 (en) | 2025-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020010075A (es) | Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos. | |
| EA202190906A1 (ru) | Рекомбинантное получение препаратов пептидов коллагена и их применение | |
| ZA202501799B (en) | Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications | |
| CO2019002609A2 (es) | Proteínas de unión recombinantes y sus usos | |
| BR112018072946A2 (pt) | proteínas de fusão a gdf15 e usos das mesmas | |
| AR114445A1 (es) | Conjugados de il-15, y sus usos | |
| MX2018005063A (es) | Polipéptidos condicionalmente activos. | |
| UY37456A (es) | Inmunoglobulinas y sus usos | |
| BR112017001940A2 (pt) | proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso | |
| MX388739B (es) | Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso. | |
| EA201891589A1 (ru) | Условно активные гетеродимерные полипептиды и способы их применения | |
| PE20240817A1 (es) | Mutantes de proteina f de rsv | |
| MX2021013417A (es) | Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos. | |
| MX2019014504A (es) | Inmunoglobulinas de union a agrecano. | |
| MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| CL2017000200A1 (es) | Célula huésped mejorada para producir proteinas | |
| MX2021001129A (es) | Metodo de purificacion de antigenos. | |
| EA201990822A1 (ru) | Иммуномодулирующие слитые белки | |
| AR102445A1 (es) | COMPOSICIONES Y MÉTODOS RELACIONADOS CON b-GLUCOSIDASA | |
| PE20161406A1 (es) | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas | |
| BR112016025450A2 (pt) | moduladores de canais de íons e usos dos mesmos | |
| MX2022003531A (es) | Polipeptidos de fusion dap10/dap12. | |
| CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina | |
| BR112021013206A2 (pt) | Bibliotecas de peptídeos e respectivos métodos de uso | |
| CL2019000099A1 (es) | Factor vii de coagulación de larga duración y métodos para producir el mismo. |